Instrument Inactif

Communiqués Nutriband Inc Other OTC

Actions

US67092M1099

Equipement, fournitures et distribution médicale

Communiqués

01/10	Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders	GL
29/09	Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis	GL
25/09	Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board	GL
22/09	Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing	GL
09/09	Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit	GL
08/09	Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch	GL
13/08	Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight	GL
15/05	Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference	GL
30/04	Nutriband : Annual Report for Fiscal Year Ending January 31, 2026 (Form 10-K)	PU
22/04	Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast	GL
30/03	Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch	GL
18/03	Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica	GL
17/02	Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica	GL
17/02	Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica	GL
30/01	Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points	GL
31/12	Nutriband CEO Publishes Letter to Shareholders	GL
29/12	Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio	GL
18/12	Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration	GL
18/12	Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction	GL
18/12	Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction	AQ
28/10/25	REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch	GL
28/10/25	Nutriband Inc. (NASDAQ:NTRB) Targets the Opioid Safety Gap in a Multi-Billion-Dollar Market	AQ
28/10/25	Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch	GL
27/10/25	Nutriband Co-Founder Gareth Sheridan Returns as CEO	GL
27/10/25	Nutriband Co-Founder Gareth Sheridan Returns as CEO	AQ